Sai Life Sciences has informed that the Board of Directors of the Company has approved and allotted 19,007 and 1,10,000 fully paid-up equity shares of Re.1 each upon exercise of options granted under ESOP 2008 and MESOP 2018 respectively vide their Board Meeting held on 22 February, 2026. The details required under Regulation 10(c) of SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 are enclosed as Annexure-A. Further, the details required as per SEBI Circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11 November 2024 are enclosed as Annexure-B.
The above information is a part of company’s filings submitted to BSE.
